Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New German Reimbursement Process Splits Opinion Ahead Of First Assessments

Executive Summary

Several drug firms – including, most vociferously, Eli Lilly & Co. – have already concluded that Germany's tough new reimbursement laws are the root of much evil. But others are taking more of a wait-and-see approach to the new system, which demands that companies provide compelling proof, upfront, of the added benefit of their drugs over existing therapies.

You may also be interested in...



German HTA Blueprint Could Be Imposed On Greece

Germany’s role in preparing a health reform agreement between Greece and the World Health Organization may lead to a G-BA/IQWiG-style HTA process being introduced in the Hellenic Republic.

Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher

Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.

U.S. Provides Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher

Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel